Anastasia Georgakopoulou

Anastasia Georgakopoulou

Auto-generated profile, based on publicly available information

Anastasia Georgakopoulou

Cancer Research UK Scotland Institute, Glasgow, G61 1BD, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2024 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
CKChristos Kiourtis
Christos Kiourtis
MTMaria Terradas-Terradas
Maria Terradas-Terradas
LGLucy M. Gee
Lucy M. Gee
SMStephanie May
Stephanie May
AGAnastasia Georgakopoulou
Anastasia Georgakopoulou
TBThomas G. Bird
Thomas G. Bird
Cellular senescence is not only associated with ageing but also impacts physiological and pathological processes, such as embryonic development and wound healing. Factors secreted by senescent cells affect their microenvironment and can induce spreading of senescence locally. Acute severe liver disease is associated with hepatocyte senescence and frequently progresses to multi-organ failure. Why the latter occurs is poorly understood. Here we demonstrate senescence development in extrahepatic organs and associated organ dysfunction in response to liver senescence using liver injury models and genetic models of hepatocyte-specific senescence. In patients with severe acute liver failure, we show that the extent of hepatocellular senescence predicts disease outcome, the need for liver transplantation and the occurrence of extrahepatic organ failure. We identify the TGFβ pathway as a critical mediator of systemic spread of senescence and demonstrate that TGFβ inhibition in vivo blocks senescence transmission to other organs, preventing liver senescence induced renal dysfunction. Our results highlight the systemic consequences of organ-specific senescence, which, independent of ageing, contributes to multi-organ dysfunction.

19 February 2025 in Nature
Verified
Journal Article
Open access
PDF file
MMMiryam Müller
Miryam Müller
SMStephanie May
Stephanie May
HHHolly Hall
Holly Hall
Tim KendallTim Kendall
Tim Kendall
LMLynn McGarry
Lynn McGarry
TBThomas G. Bird
Thomas G. Bird
Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is a leading cause of cancer-related mortality worldwide1,2. HCC occurs typically from a background of chronic liver disease, caused by a spectrum of predisposing conditions. Tumour development is driven by the expansion of clones that accumulate progressive driver mutations3, with hepatocytes the most likely cell of origin2. However, the landscape of driver mutations in HCC is broadly independent of the underlying aetiologies4. Despite an increasing range of systemic treatment options for advanced HCC, outcomes remain heterogeneous and typically poor. Emerging data suggest that drug efficacies depend on disease aetiology and genetic alterations5,6. Exploring subtypes in preclinical models with human relevance will therefore be essential to advance precision medicine in HCC7. Here we generated a suite of genetically driven immunocompetent in vivo and matched in vitro HCC models. Our models represent multiple features of human HCC, including clonal origin, histopathological appearance and metastasis. We integrated transcriptomic data from the mouse models with human HCC data and identified four common human–mouse subtype clusters. The subtype clusters had distinct transcriptomic characteristics that aligned with the human histopathology. In a proof-of-principle analysis, we verified response to standard-of-care treatment and used a linked in vitro–in vivo pipeline to identify a promising therapeutic candidate, cladribine, that has not previously been linked to HCC treatment. Cladribine acts in a highly effective subtype-specific manner in combination with standard-of-care therapy.

10 July 2023 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
TSToshiyasu Suzuki
Toshiyasu Suzuki
AKAnna Kilbey
Anna Kilbey
NCNuria Casa-Rodríguez
Nuria Casa-Rodríguez
ALAmy Lawlor
Amy Lawlor
AGAnastasia Georgakopoulou
Anastasia Georgakopoulou
SCSeth B. Coffelt
Seth B. Coffelt
Intraepithelial lymphocytes (IEL) expressing γδ T-cell receptors (γδTCR) play key roles in elimination of colon cancer. However, the precise mechanisms by which progressing cancer cells evade immunosurveillance by these innate T cells are unknown. Here, we investigated how loss of the Apc tumor suppressor in gut tissue could enable nascent cancer cells to escape immunosurveillance by cytotoxic γδIELs. In contrast with healthy intestinal or colonic tissue, we found that γδIELs were largely absent from the microenvironment of both mouse and human tumors, and that butyrophilin-like (BTNL) molecules, which can critically regulate γδIEL through direct γδTCR interactions, were also downregulated in tumors. We then demonstrated that β-catenin activation through loss of Apc rapidly suppressed expression of the mRNA encoding the HNF4A and HNF4G transcription factors, preventing their binding to promoter regions of Btnl genes. Reexpression of BTNL1 and BTNL6 in cancer cells increased γδIEL survival and activation in coculture assays but failed to augment their cancer-killing ability in vitro or their recruitment to orthotopic tumors. However, inhibition of β-catenin signaling via genetic deletion of Bcl9/Bcl9L in either Apc-deficient or mutant β-catenin mouse models restored Hnf4a, Hnf4g, and Btnl gene expression and γδ T-cell infiltration into tumors. These observations highlight an immune-evasion mechanism specific to WNT-driven colon cancer cells that disrupts γδIEL immunosurveillance and furthers cancer progression.

1 May 2025 in Disease Models & Mechanisms
Verified
Journal Article
Open access
SMStephanie May
Stephanie May
KSKatrina Stevenson
Katrina Stevenson
BABashaer Alqarafi
Bashaer Alqarafi
KSKyi Lai Yin Swe
Kyi Lai Yin Swe
ABAlgernon Bloom
Algernon Bloom
TBThomas G. Bird
Thomas G. Bird
Liver tumours, both primary and metastatic, are diseases of unmet clinical need. Hepatocellular carcinoma (HCC), the most common primary liver tumour, like many other cancers, can be treated by stereotactic ablative radiotherapy (SABR), reducing off-target effects of radiation on local anatomical structures. However, integrating all the necessary components for stereotactic irradiation of HCC in murine models has not yet been reported. Here, we provide the development and detailed characterisation of a murine SABR model combining magnetic resonance imaging- and computed tomography (CT)-guided delineation of the tumour, together with CT-guided liver tumour radiotherapy. The model enables accurate delivery of clinically relevant doses of radiotherapy with good tolerability and on-target tumour responses in models with otherwise universally progressive disease. The development of this preclinical modelling platform paves the way for its integration into multimodal therapeutic and mechanistic testing in preclinical murine models of metastatic and primary liver tumours, including HCC.

3 December 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RBRachel L. Baird
Rachel L. Baird
DMDavid Mason
David Mason
KRKai Rakovic
Kai Rakovic
FBFiona Ballantyne
Fiona Ballantyne
IPIan R. Powley
Ian R. Powley
JQJohn Le Quesne
John Le Quesne
Multiplexed methods for the detection of protein expression generate extremely data-rich images of intact tissue sections. These images are invaluable for the quantification and analysis of complex biology and biomarker development. However, their interpretation presents a considerable analytical challenge. Cell segmentation from images is a key bottleneck and a major focus of research activity in artificial intelligence. Most current methods depend initially on the use of a nuclear counterstain to identify nuclear boundaries, which is a relatively straightforward task. The cellular boundary is then assigned either by expansion of the nuclear outline, or by the use of membrane or cytoplasm-specific stains to delineate cell boundaries, or by some combination of the two. The task is critical, as inaccurate segmentation leads to information loss and data contamination from neighbouring cells. Increasingly sophisticated methods are being developed to address these issues, but each has its own shortcomings. We present an alternative method which is inspired by the fact that the assignation of a cellular phenotype ‘by eye’ does not depend upon the accurate identification of cell boundaries. We present an easy-to-use deep learning-based cellular phenotyping method which leverages this human capacity to assign phenotypes without segmenting the entire cell, and which can accurately phenotype cells based on nuclear segmentation alone. Using human ground truth annotations of entire cellular regions, we developed a classifier leveraging the U-Net architecture within a commercially available deep learning image analysis platform, but the principle is transferrable to any deep-learning framework. Crucially, training requires only a single example of each compartmental stain (nuclear/cytoplasmic/membranous). The resulting algorithm assigns class identities to cells with nuclear labelling alone, without the need for whole cell expansion. The method is highly novel, broadly generalisable, and comparable in accuracy to intensity-based phenotyping methods, bridging the gap between inaccurate cellular segmentation and accurate phenotype generation.

3 August 2023
Verified
Other
Open access
PDF file
TSToshiyasu Suzuki
Toshiyasu Suzuki
AKAnna Kilbey
Anna Kilbey
NCNuria Casa-Rodríguez
Nuria Casa-Rodríguez
ALAmy Lawlor
Amy Lawlor
AGAnastasia Georgakopoulou
Anastasia Georgakopoulou
SCSeth B. Coffelt
Seth B. Coffelt
WNT expression is independent of BTN3A1 and BTN2A1